Overview

This trial is active, not recruiting.

Condition breast cancer
Treatments pegfilgrastim, cyclophosphamide, epirubicin hydrochloride, fluorouracil, paclitaxel, adjuvant therapy
Phase phase 3
Sponsor Gruppo Italiano Mammella (GIM)
Start date April 2003
Trial size 2000 participants
Trial identifier NCT00433420, CDR0000528056, EU-20681, GIM-2

Summary

RATIONALE: Drugs used in chemotherapy, such as epirubicin, cyclophosphamide, paclitaxel, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Colony-stimulating factors, such as pegfilgrastim, may increase the number of immune cells found in bone marrow or peripheral blood and may help the immune system recover from the side effects of chemotherapy. Giving combination chemotherapy and pegfilgrastim after surgery may kill any tumor cells that remain after surgery. It is not yet known whether combination chemotherapy is more effective with or without fluorouracil and/or pegfilgrastim in treating breast cancer.

PURPOSE: This randomized phase III trial is studying combination chemotherapy to compare how well it works when given with or without fluorouracil and/or pegfilgrastim in treating women with node-positive breast cancer.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Primary purpose treatment

Primary Outcomes

Measure
Disease-free survival
time frame:

Secondary Outcomes

Measure
Overall survival
time frame:
Toxicity
time frame:

Eligibility Criteria

Female participants from 18 years up to 70 years old.

DISEASE CHARACTERISTICS: - Histologically confirmed primary breast cancer - No histology other than carcinoma - Node-positive disease - Must have at least 1 involved axillary node or internal mammary node - Previously resected disease - Has undergone radical surgery (i.e., mastectomy or conservative surgery) with axillary node dissection within the past 7 weeks - No inflammatory carcinoma - No prior or concurrent ipsilateral or contralateral invasive breast carcinoma - No metastatic disease, including metastasis in the ipsilateral supraclavicular lymph nodes - Hormone receptor status not specified PATIENT CHARACTERISTICS: - Female - Menopausal status not specified - ECOG performance status 0-1 - Absolute neutrophil count ≥ 1,500/mm³ - WBC ≥ 4,000/mm³ - Platelet count ≥ 100,000/mm³ - Hemoglobin ≥ 9 g/dL - Bilirubin ≤ 1.5 times upper limit of normal (ULN) - Creatinine ≤ 1.5 times ULN - AST and ALT ≤ 2.5 times ULN - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No chronic liver or renal disease - No other serious medical illness requiring medication - No other malignancy except adequately treated, cone-biopsied in situ carcinoma of the cervix or basal cell or squamous cell carcinoma of the skin - No symptomatic peripheral neuropathy > grade 2 - No hypersensitivity to study drugs or their components - No recent myocardial infarction, congestive heart failure, or serious arrhythmia PRIOR CONCURRENT THERAPY: - See Disease Characteristics - No prior chemotherapy - No prior cytotoxic regimens - No prior radiation therapy, except for intraoperative radiation therapy

Additional Information

Official title A Phase III Randomized Study of EC Followed by Paclitaxel Versus FEC Followed by Paclitaxel, All Given Either Every 3 Weeks or 2 Weeks Supported by Pegfilgrastim, for Node Positive Breast Cancer Patients
Description OBJECTIVES: Primary - Compare the efficacy of adjuvant therapy comprising epirubicin hydrochloride, cyclophosphamide, and paclitaxel with vs without fluorouracil and/or pegfilgrastim in women with node-positive breast cancer. Secondary - Compare the overall survival of patients treated with these regimens. - Compare the safety of these regimens in these patients. OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 4 treatment arms. - Arm I: Patients receive epirubicin hydrochloride IV and cyclophosphamide IV on day 1. Treatment repeats every 3 weeks for 4 courses. Patients then receive paclitaxel IV over 3 hours on day 1. Treatment with paclitaxel repeats every 3 weeks for 4 courses. - Arm II: Patients receive fluorouracil IV, epirubicin hydrochloride IV, and cyclophosphamide IV on day 1. Treatment repeats every 3 weeks for 4 courses. Patients then receive paclitaxel as in arm I. - Arm III: Patients receive epirubicin hydrochloride IV and cyclophosphamide IV on day 1 and pegfilgrastim subcutaneously (SC) on day 4. Treatment repeats every 2 weeks for 4 courses. Patients then receive paclitaxel IV over 3 hours on day 1 and pegfilgrastim subcutaneously (SC) on day 4. Treatment with paclitaxel and pegfilgrastim repeats every 2 weeks for 4 courses. - Arm IV: Patients receive fluorouracil IV, epirubicin hydrochloride IV, and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 4. Treatment repeats every 2 weeks for 4 courses. Patients then receive paclitaxel and pegfilgrastim as in arm III. In all arms, treatment continues in the absence of disease progression or unacceptable toxicity. After completion of chemotherapy with or without pegfilgrastim, patients may undergo external-beam radiation therapy at the discretion of treating center. Patients with positive estrogen and/or progesterone receptor tumor receive tamoxifen for 5 years. After completion of study treatment, patients are followed periodically for 5 years and then annually thereafter. PROJECTED ACCRUAL: A total of 2,000 patients will be accrued for this study.
Trial information was received from ClinicalTrials.gov and was last updated in August 2013.
Information provided to ClinicalTrials.gov by National Cancer Institute (NCI).